Novartis AG
NVS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVS
Novartis AG is a global pharmaceutical company focused on innovative medicines across four core therapeutic areas and advanced technology platforms including radioligand therapy, xRNA, and cell and gene therapy, with a strong pipeline and recent financial outperformance.
Key risk: Pipeline development failure
BioSniper Score
Based on 4 of 6 signals
Market Cap
$292.35B
Cash Runway
—
Lead Asset
[177lu]lu-psma-617 (Phase 4)Next Catalyst
Phase2_Start · Sep 10, 2026Financial data as of Dec 31, 2025.
Tracking 68 pipeline candidates · 472 clinical trials · 89 catalysts · 53 FDA decisions for Novartis AG.
Novartis AG is a global pharmaceutical company focused on innovative medicines across four core therapeutic areas and advanced technology platforms including radioligand therapy, xRNA, and cell and gene therapy, with a strong pipeline and recent financial outperformance.
- Novartis focuses on four core therapeutic areas and three advanced technology platforms: radioligand therapy, xRNA, and cell and gene therapy [sec · filed 2026-02-04].
- In 2025, the company achieved 7 key approvals and 15 regulatory filings, exceeding its pipeline targets [sec · filed 2025-01-31].
- Cash and equivalents stood at $2,579.0M as of 2025-12-31, with shareholders' equity of $46,667.0M and total debt of $37,122.0M [sec].
- The company delivered a core margin of 40.1% in 2025, achieving its 2027 external guidance two years ahead of plan [sec · filed 2026-02-04].
- Novartis has executed more than 30 strategic deals over the past two years, bolstering its pipeline and mid-2030s outlook [sec · filed 2025-11-20].
What works
- Strong pipeline execution: 7 key approvals and 15 regulatory filings in 2025, exceeding targets [sec · filed 2025-01-31].
- Financial outperformance: core margin of 40.1% achieved two years ahead of 2027 guidance [sec · filed 2026-02-04].
- Strategic deal-making: over 30 deals in two years, including late-stage clinical programs and acquisitions [sec · filed 2025-11-20].
- Advanced platform leadership: investment in radioligand therapy, xRNA, and cell and gene therapy positions for future innovation [sec · filed 2026-02-04].
What to weigh
- Pipeline risk: failure to progress late-stage assets could negatively impact business and financial results [sec · filed 2026-02-04].
- Clinical trial challenges: difficulty recruiting patients in the US due to competition from other trials [sec · filed 2026-02-04].
- Technological disruption: inability to keep pace with AI and other technological changes may lead to lower revenues and margins [sec · filed 2026-02-04].
- Dependence on innovation: success of cell, gene, and radioligand therapies depends on uncertain scientific and execution factors [sec · filed 2026-02-04].
From the filings
Quoted directly from source documents.
Novartis achieved 7 key approvals in 2025, exceeding its target of 6.
“7 (vs. target of 6) key approvals secured: iptacopan (Fabhalta) for PNH approved in EU, China and Japan, and for IgAN approved in the US, Kisqali for early breast cancer approved in the US and EU, as well as Scemblix 1L in the US.”
SEC filings · January 31, 2025
Novartis delivered a core margin of 40.1% in 2025, ahead of its 2027 guidance.
“Delivered a core margin of 40.1%, achieving our 2027 external guidance two years ahead of plan underscoring both the strength of our business performance and our disciplined”
SEC filings · February 4, 2026
Novartis focuses on three advanced technology platforms: radioligand therapy, xRNA, and cell and gene therapy.
“We focus on two established platforms -- chemistry and biotherapeutics -- in addition to three advanced platforms: radioligand therapy, xRNA, and cell and gene therapy.”
SEC filings · February 4, 2026
Novartis executed more than 30 strategic deals over the past two years.
“Over the past two years, we have executed more than 30 strategic deals, bolstering our pipeline and strengthening the outlook of the business in the mid-2030s and beyond.”
SEC filings · November 20, 2025
Catalyst timeline
- 2026-09-10 · Phase 2 Start: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess th — Initiation of a Phase IIb study for an undisclosed asset, assessing dose range in a controlled setting.
- 2026-09-10 · Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha — Topline data readout for 177Lu-PSMA-617 in a Phase III study, comparing it to a change in therapy.
- 2026-09-23 · Phase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V — Topline data readout for JDQ443 in a Phase III study evaluating efficacy and safety.
- 2026-10-26 · Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evalua — Topline data readout for inclisiran in a Phase IIIb study evaluating its effects.
- 2026-10-30 · Phase 2 Start: VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy — Initiation of a Phase 2 study for arumakimig, evaluating efficacy over 52 weeks.
- 2026-11-23 · Phase 3 Topline: A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses — Topline data readout for a vaso-occlusive disease treatment, assessing two doses.
- 2026-12-30 · Phase 3 Topline: An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Com — Topline data readout for a long-term safety roll-over study in tuberous sclerosis complex.
- 2027-01-01 · Phase 2 Start: An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who — Initiation of a Phase 2 roll-over study for alpelisib to assess long-term safety.
Risks & what to watch (4)›
Key risks
- Pipeline development failure — Failure to progress late-stage assets could negatively impact business and financial results [sec · filed 2026-02-04].
- Clinical trial recruitment challenges — Difficulty recruiting patients in the US due to competition from other trials [sec · filed 2026-02-04].
- Technological disruption risk — Inability to keep pace with AI and other technological changes may lead to lower revenues and margins [sec · filed 2026-02-04].
- Dependence on innovative therapies — Success of cell, gene, and radioligand therapies depends on uncertain scientific and execution factors [sec · filed 2026-02-04].
What to watch
- Upcoming Phase 3 topline data for PSMAfore (177Lu-PSMA-617) on 2026-09-10 [catalyst].
- Phase 3 topline data for JDQ443 on 2026-09-23 [catalyst].
- Phase 3 topline data for inclisiran on 2026-10-26 [catalyst].
- Phase 2 start for arumakimig on 2026-10-30 [catalyst].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Novartis AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Novartis AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.38
Lead: Approved
68 candidates
89 upcoming, next in ~11d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,588
Total value held
$19.39B
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 8,527,037 | $1.30B |
| dimensional fund advisors lp | 8,110,116 | $1.24B |
| primecap management co/ca/ | 7,567,354 | $1.16B |
| dodge & cox | 6,967,383 | $1.06B |
| goldman sachs group inc | 6,525,771 | $996.8M |
| bank of america corp /de/ | 4,962,794 | $758.1M |
| janus henderson group plc | 4,551,876 | $695.3M |
| franklin resources inc | 3,409,944 | $520.9M |
| blackrock, inc. | 2,949,760 | $450.6M |
| northern trust corp | 2,786,228 | $425.6M |
Showing top 10 of 1,588 institutional holders of Novartis AG. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.2%
- Days to cover
- 2.9
- Shares short
- 4,488,888
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Novartis AG?
Novartis AG is a global pharmaceutical company focused on innovative medicines across four core therapeutic areas and advanced technology platforms including radioligand therapy, xRNA, and cell and gene therapy, with a strong pipeline and recent financial outperformance.
What is Novartis AG's lead drug candidate?
Novartis AG's most advanced tracked candidate is [177lu]lu-psma-617 (Phase 4) for Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What is Novartis AG's next catalyst?
Novartis AG's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess th" — expected September 10, 2026.
Who is the CEO of Novartis AG?
Dr. Vasant Narasimhan M.D. is the chief executive officer of Novartis AG (NVS).
Where is Novartis AG headquartered?
Novartis AG (NVS) is headquartered in Basel, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.